1. Home
  2. AERT vs IMMP Comparison

AERT vs IMMP Comparison

Compare AERT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeries Technology Inc.

AERT

Aeries Technology Inc.

N/A

Current Price

$7.10

Market Cap

39.7M

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.27

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AERT
IMMP
Founded
2012
1987
Country
Singapore
Australia
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
42.4M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
AERT
IMMP
Price
$7.10
$0.27
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
★ $5.50
AVG Volume (30 Days)
14.7K
★ 324.8K
Earning Date
02-09-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 110.87
N/A
EPS
★ 0.27
N/A
Revenue
★ $70,014,000.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$26.81
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.26
$0.26
52 Week High
$7.65
$3.53

Technical Indicators

Market Signals
Indicator
AERT
IMMP
Relative Strength Index (RSI) 52.10 29.26
Support Level $6.11 N/A
Resistance Level $7.30 $0.40
Average True Range (ATR) 0.28 0.02
MACD -0.00 -0.01
Stochastic Oscillator 64.19 7.86

Price Performance

Historical Comparison
AERT
IMMP

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: